All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld MedTech Perspectives » NIH spending: Time for a closer look at how our government prioritizes spending at NIH and whether the default priorities really make sense

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Cardiovascular / Oncology / National Institutes of Health

NIH spending: Time for a closer look at how our government prioritizes spending at NIH and whether the default priorities really make sense

May 1, 2011
By Mark McCarty
No Comments

Politics, economics, and NIH spending priorities

By MARK McCARTY

Medical Device Daily Washington Editor

Government that makes sense. It's what we all dream of, but when it comes to spending priorities at the U.S. National Institutes of Health, we might as well wish to lose weight on the see-food diet. FYI: That's the diet on which when you see food, you eat it.

What do I mean? Here's what I mean.

NIH's budget for the National Cancer Institute in fiscal 2010 was a bit more than $5.1 billion (click here), but the budget for the National Heart, Lung, and Blood Institute was comparatively deficient at less than $3.1 billion. Even your nephew in middle school knows that heart disease still kills more people of both sexes over the age of 40 than anything else, including cancer, the disease that seems to spark more sympathy than any other.

I'll admit that the cost of treatment of cancer is very expensive, but the latest implantable defibrillator isn't cheap, either, and medical science is still baffled by the unpredictability of sudden cardiac death. The American Heart Association (Dallas) estimates that in 2009, the total cost of heart disease in the U.S. exceeded $475 billion (click here), whereas a similar estimate for cancer, by the reckoning of the American Cancer Society (ACS; Atlanta), was $228 billion for the previous year (click here). So what we have is one condition (heart disease) is twice as costly to society as a disease (cancer) that gets 66% more NIH money.

We all know that one good way to lose your job for good is to be impaired, cognitively or physically. Would you like to know what NIH budgets for its arthritis and muscular diseases programs? The National Institute for Arthritis and Musculoskeletal and Skin Disease got less than $600 million in fiscal 2010. CDC reported in 2007 that the anticipated cost of arthritis for that calendar year would be $127 billion, more than half the cost of cancer (click here). That doesn't account for all the other diseases examined by NIAMS, but NCI gets $5.1 billion and NIAMS gets only $600 million? That's conservatively two thirds of the cost of cancer, but less than an eighth of NCI's budget.

How about stroke and neurological diseases? These are handled by the National Institute for Neurological Disorders and Stroke, or NINDS. The answer is (drum roll, please), NINDS got a bit more than $1.6 billion in fiscal 2010. According to the Alzheimer's Association (Chicago), the cost of care for Alzheimer's will be $20 trillion between 2010 and 2050 (click here). That's an average of $500 billion a year. One fourth the money of cancer, twice the cost.

No wonder the folks in Washington can't balance the budget.

As a teenager, if I tried to give my father an explanation that just didn't stand up to scrutiny, he'd ask me why I was trying to hand him a snow job. Any rationalization for all this would be nothing but a snow job. I'm pretty sure that's what my father would say, anyway.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing